Structures by: Navasardyan M. A.
Total: 12
3-phenylserine peroxosolvate
C9H11NO3,H2O2
CrystEngComm (2018) 20, 46 7413
a=18.7167(5)Å b=18.7167(5)Å c=5.7741(3)Å
α=90.00° β=90.00° γ=90.00°
Sarcosine peroxosolvate
C3H7NO2,H2O2
CrystEngComm (2018) 20, 46 7413
a=13.1669(7)Å b=6.3974(4)Å c=10.7817(6)Å
α=90.00° β=90.6050(10)° γ=90.00°
C6H10N2O2,2(H2O2)
C6H10N2O2,2(H2O2)
CrystEngComm (2019) 21, 33 4961
a=7.439(2)Å b=8.215(2)Å c=8.298(2)Å
α=97.332(4)° β=104.578(4)° γ=104.053(4)°
C4H6N2O2,2(H2O2)
C4H6N2O2,2(H2O2)
CrystEngComm (2019) 21, 33 4961
a=5.654(3)Å b=5.802(3)Å c=6.648(3)Å
α=76.505(8)° β=66.440(7)° γ=79.984(8)°
C6H10N2O2,H2O2
C6H10N2O2,H2O2
CrystEngComm (2019) 21, 33 4961
a=8.2527(13)Å b=6.6341(10)Å c=15.034(2)Å
α=90.00° β=99.847(2)° γ=90.00°
C12H24O6,2(H4N2)
C12H24O6,2(H4N2)
CrystEngComm (2019) 21, 38 5693
a=7.7920(7)Å b=14.2386(13)Å c=7.9049(7)Å
α=90° β=94.487(1)° γ=90°
C16H36N,C2H3O2,H4N2
C16H36N,C2H3O2,H4N2
CrystEngComm (2019) 21, 38 5693
a=16.8256(5)Å b=17.1025(5)Å c=15.0186(5)Å
α=90° β=90° γ=90°
C16H36N,C2H3O2,0.902(H4N2),0.049(H4O2)
C16H36N,C2H3O2,0.902(H4N2),0.049(H4O2)
CrystEngComm (2019) 21, 38 5693
a=16.7939(4)Å b=17.0018(5)Å c=15.0341(3)Å
α=90° β=90° γ=90°
C4H6N2O2,1.786(H2O2),0.214(H2O)
C4H6N2O2,1.786(H2O2),0.214(H2O)
CrystEngComm (2019) 21, 33 4961
a=5.5006(8)Å b=5.8258(8)Å c=6.5611(9)Å
α=76.395(2)° β=67.816(2)° γ=79.145(2)°
Pipecolic acid diperoxosolvate
C6H11NO2,2(H2O2)
Acta Crystallographica Section E (2020) 76, 8 1331-1335
a=6.5739(4)Å b=22.9278(15)Å c=6.0647(4)Å
α=90° β=93.7700(10)° γ=90°
4-metacryloxyphenyl 4-<i>n</i>-hexyloxybenzoate
C23H26O5
Acta Crystallographica Section E (2017) 73, 7 1052-1055
a=5.6805(3)Å b=8.3846(5)Å c=21.4864(12)Å
α=99.1910(10)° β=92.7190(10)° γ=91.7010(10)°
2,3,5,6-Tetrakis(pyridin-2-yl)pyrazine hydrogen peroxide 4.75-solvate
C24H16N6,4.75(H2O2)
Acta crystallographica. Section E, Crystallographic communications (2017) 73, Pt 11 1793-1796
a=19.000(7)Å b=7.382(3)Å c=20.212(7)Å
α=90.00° β=114.271(5)° γ=90.00°